results
Last reviewed 01/2018
- there were 939 atherosclerotic events in the clopidogrel group during 17,636 patient-years at risk, an average rate per year of 5.32%
- there were 1031 events in the aspirin group during 17,519 patient-years risk, an average rate per year of 5.83%
- the relative risk reduction was 8.7% (95% CI 0.3-16.5) in favour of clopidogrel (p=0.043)
- there was no significant differences between aspirin and clopidogrel in relation to the risk of death from any cause
- calculating the number to needed to treat from the CAPRIE trial data, it would be necessary to use clopidogrel instead of aspirin in approximately 200 patients for 1 year to avert one additional major clinical event